Laurus Labs Ltd - LAURUS LABS Share Price

Sector: Pharmaceuticals | ISIN: INE947Q01028
₹ 449.10 (-1.60%) icon23 May, 2024, 10:59:59 AM
Open
₹ 457.05
Prev. Close
₹ 456.40
Turnover(lac)
₹ 0.02
Day's High
₹ 457.95
Day's Low
₹ 444.50
52 Wk High
₹ 471.00
52 Wk Low
₹ 311.55
Book Value
₹ 79.42
Face Value
₹ 2.00
Mkt. Cap (Cr.)
₹ 24,204.96
P/E
110.00
EPS
4.15
Div. Yield
0.09

Laurus Labs Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/23/2024 10:59:59 AM

    ₹ 449.1 -7.30 -1.60
  • Open
  • ₹ 457.05
  • Prev. Close
  • ₹ 456.4
  • Turnover(Lac.)
  • ₹ 1,582
  • Day's High
  • ₹ 457.95
  • Day's Low
  • ₹ 444.5
  • 52 Week's High
  • ₹ 471
  • 52 Week's Low
  • ₹ 311.55
  • Book Value
  • ₹ 79.42
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 24,204.96
  • P/E
  • 110
  • EPS
  • 4.15
  • Divi. Yield
  • 0.09

Laurus Labs Ltd Corporate Actions

25 Apr , 2024

12:00 AM

Dividend

Dividend amount: 0.4
Announcement date: 25 Apr , 2024

View Details

18 Apr , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

18 Apr , 2024

12:00 AM

17 Jan , 2024

12:00 AM

17 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

20 Oct , 2023

12:00 AM

Dividend

Dividend amount: 0.4
Announcement date: 20 Oct , 2023

View Details

13 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

13 Oct , 2023

12:00 AM

11 Sep , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

20 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

20 Jul , 2023

12:00 AM

27 Apr , 2023

12:00 AM

AGM

Announcement date: 27 Apr , 2023

View Details

27 Apr , 2023

12:00 AM

BookCloser

View Details

No Record Found


Laurus Labs Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Laurus Labs Ltd SHAREHOLDING SNAPSHOT
23 May , 2024 | 11:19 AM

PROMOTER - TOTAL27.19%

Indian: 27.19%

Foreign: 0%

NON-PROMOTER - TOTAL 72.81%

Institutions: 37.75%

Non-Institutions: 35.07%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Laurus Labs Ltd FINANCIALS

View Profit & Loss Graph

Laurus Labs Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Laurus Labs Ltd

  • M V G Rao
  • Chairman & Independent Directo
  • CHAVA SATYANARAYANA
  • Executive Director & CEO
  • VENKATA RAVI KUMAR VANTARAM
  • Executive Director & CFO
  • Chandrakanth Chereddi
  • Non Executive Director
  • Aruna Bhinge
  • Independent Non Exe. Director
  • Rajesh Koshy Chandy
  • Independent Non Exe. Director
  • Ravindranath Kancherla
  • Independent Non Exe. Director
  • Venkata Lakshmana Rao Chunduru
  • Executive Director

Summary

Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others. The company currently operates 4 manufacturing facilities in Visakhapatnam, Andhra Pradesh. Three of these facilities manufacture APIs and ingredients, while the fourth facility produces Finished Dosage Formulations (FDFs) and one API. The companys strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing donor-funded access-to-medicines markets of Sub-Saharan Africa, South-East Asia and Latin America. The company also has growing synthesis and nutraceutical/ cosmeceutical ingredients businesses. Further, it is increasingly focused towards growing its integrated generics finished dosage forms (FDFs) business in which it has made significant investments.Laurus Labs operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis and Ingredients. Its Generics - API business comprises the development,... Read More


Reports by Laurus Labs Ltd


Reports by Laurus Labs Ltd

Company FAQ

No Record Found